Abstract
Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.
Keywords: Metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, breath test
Current Pharmaceutical Design
Title: Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome
Volume: 13 Issue: 21
Author(s): Giuseppe Palasciano, Antonio Moschetta, Vincenzo O. Palmieri, Ignazio Grattagliano, Gianluca Iacobellis and Piero Portincasa
Affiliation:
Keywords: Metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, breath test
Abstract: Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.
Export Options
About this article
Cite this article as:
Giuseppe Palasciano , Antonio Moschetta , Vincenzo O. Palmieri , Ignazio Grattagliano , Gianluca Iacobellis and Piero Portincasa , Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome, Current Pharmaceutical Design 2007; 13 (21) . https://dx.doi.org/10.2174/138161207781039652
DOI https://dx.doi.org/10.2174/138161207781039652 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Hypotensive Agents from Verbesina Caracasana: Structure, Synthesis and Pharmacology
Current Medicinal Chemistry Oligonucleotide-based Gene Therapy for Cardiovascular Disease Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs
Current Drug Targets MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Preface
Current Cardiology Reviews AMI and Anabolic-Androgenic Steroids: Case Report with Systematic Review
Current Cardiology Reviews Insulin Resistance and Alzheimers Disease Pathogenesis: Potential Mechanisms and Implications for Treatment
Current Alzheimer Research Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Pediatric Obesity Epidemic: Problem and Solutions
Current Pharmaceutical Design Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Personalized Medicine in Psoriasis: Concept and Applications
Current Vascular Pharmacology Potential Therapeutic Targeting of Platelet-Mediated Cellular Interactions in Atherosclerosis and Inflammation
Current Medicinal Chemistry No Effect of Metformin on Ovarian Cancer Survival: A Systematic Review and Meta-Analysis of Cohort Studies
Current Pharmaceutical Design Renoprotection with Anti-Hypertensives: Reduction of Proteinuria and Improvement of Oxygenation via Inhibition of the Renin-Angiotensin System
Current Hypertension Reviews Global Safety of Coxibs and NSAIDs
Current Topics in Medicinal Chemistry Repetitive Transient Phosphodiesterase-3 Inhibition Eliminates Non-ischemic Cardiac Remodeling and Failure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Leptin and Inflammation
Current Immunology Reviews (Discontinued) Cardioprotection by Regular Ethanol Consumption: Potential Mechanisms and Clinical Application
Current Drug Abuse Reviews A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications
Current Drug Metabolism ω-3 Polyunsaturated Fatty Acids Effects on the Cardiometabolic Syndrome and their Role in Cardiovascular Disease Prevention: An Update from the Recent Literature
Recent Advances in Cardiovascular Drug Discovery (Discontinued)